DEXCOM INC
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 8, 2024
DXCM$81.07+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
DexCom, Inc.
Consolidated Statements of Operations
| Twelve Months EndedDecember 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| (In millions, except per share data) | |||
| Revenue | $3,622.3 | $2,909.8 | $2,448.5 |
| Cost of sales | 1,333.4 | 1,026.7 | 768.0 |
| Gross profit | 2,288.9 | 1,883.1 | 1,680.5 |
| Operating expenses: | |||
| Research and development | 505.8 | 484.2 | 517.1 |
| Collaborative research and development fee | — | — | 87.1 |
| Selling, general and administrative | 1,185.4 | 1,007.7 | 810.5 |
| Total operating expenses | 1,691.2 | 1,491.9 | 1,414.7 |
| Operating income | 597.7 | 391.2 | 265.8 |
| Other income (expense), net | 112.7 | (0.4) | (9.0) |
| Income before income taxes | 710.4 | 390.8 | 256.8 |
| Income tax expense | 168.9 | 49.6 | 39.9 |
| Net income | $541.5 | $341.2 | $216.9 |
| Basic net income per share | $1.40 | $0.88 | $0.56 |
| Shares used to compute basic net income per share | 386.0 | 389.4 | 386.9 |
| Diluted net income per share | $1.30 | $0.82 | $0.53 |
| Shares used to compute diluted net income per share | 425.5 | 427.5 | 428.8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.